Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler R3INFORCE Extraosseous Repair System - Seite 3

Disclaimer

Dr. Davies may report consulting and royalty fees from Paragon 28 in connection with the provision of product development services to Paragon 28.

Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328312304/en/

The Paragon 28 Stock at the time of publication of the news with a raise of +3,61 % to 12,34EUR on NYSE stock exchange (28. März 2024, 20:54 Uhr).